FDA recommends Novartis’s biosimilar for Enbrel in unanimous vote
pharmafile | July 14, 2016 | News story | Research and Development, Sales and Marketing | Enbrel, FDA, Novartis, Sandoz, biosimilar
Sandoz, a division of Novartis, has announced that a US Food and Drug Administration (FDA) advisory committee has recommended their proposed biosimilar for Enbrel (etanercept) in a unanimous 20-0 vote.
This news comes shortly after the FDA also recommended Amgen’s biosimilar candidate for Humira (adalimumab), also by unanimous vote. While the US has lagged behind in terms of approving biosimilars, 2016 looks set to become the year when the US begins to try catch up on the progress made by biosimilars in Europe.
For Novartis, the FDA recommended their biosimilar version of Amgen’s blockbuster for all five indications of the originator product, including rheumatoid arthritis, plaque psoriasis, psoriatic psoriasis, ankylosing spondylitis and polyarticular juvenile idiopathic arthritis.
Mark McCamish, head of global biopharmaceuticals development at Sandoz, says: “We are encouraged by today’s favourable advisory committee recommendation for our proposed biosimilar etanercept. As a global market leader in biosimilars, we are pleased to move one step closer toward our goal of expanding patient access with our proposed biosimilar etanercept.”
If finally approved by the FDA, it may however be a challenge to get the biosimilar to market. AbbVie has already taken action to block Amgen’s Humira biosimilar making it to market, and Amgen will find itself on the other side of the battle against Novartis. It may look to follow the same strategy of claiming further patent protection in a variety of areas, to prevent biosimilar versions making it to market.
Sean Murray
Related Content
MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …
Sandoz’ Ondibta receives European Commission approval for diabetes
Sandoz has announced that its Ondibta (insulin glargine) has received approval from the European Commission …
Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …
